Genesis Therapeutics is proud to announce a monumental funding milestone, having successfully raised $620 million to accelerate its mission of transforming drug discovery. Headquartered in Burlingame, CA, and equipped with a fully integrated laboratory in San Diego, Genesis Therapeutics is at the forefront of unifying artificial intelligence and biotechnology to develop breakthrough treatments for patients facing severe and devastating conditions. The newly raised funds will power the expansion of the company’s state-of-the-art generative AI platform, GEMS (Genesis Exploration of Molecular Space), which leverages deep learning predictive models, molecular simulations, and molecular generative AI to identify promising molecules for synthesis and experimental testing. This funding injection is designed to drive further innovation by enabling accelerated hit identification, lead optimization, and candidate selection while iterating through multiple cycles of AI-enabled discovery and optimization.
With GEMS, Genesis has already built a robust internal pipeline that targets high-value, data-poor, and traditionally undruggable targets—areas where its technological edge is most pronounced. The expanded capital will not only deepen the company’s pipeline across multiple therapeutic areas but will also facilitate strategic collaborations with leading industry players such as Eli Lilly and Genentech, further bolstering its research capabilities. In addition, the funds will support rapid growth of an exceptional multidisciplinary team across machine learning, computational chemistry, software development, chemistry, biology, and clinical research. This investment represents a significant step forward in the pursuit of pioneering treatments, reinforcing Genesis Therapeutics’ commitment to mitigating some of the most challenging healthcare issues through the powerful fusion of AI and biotechnology.
